OSRH — OSR Health, Inc.

—
OTC · Health Care · Health Care Equipment & Supplies · CIK 1840425 ·
Last close
$0.10
Market Cap
$3.51M
52W High
$0.90
52W Low
$0.05
ADV30
160,428
Next earnings
—
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 315,669 86,605 -3,032,914 -848,905 166,623,360 1,499,603 41,714,542
Mar 2026 484,057 160,281 -3,667,184 -2,931,461 172,187,773 1,566,701 44,796,654
Dec 2025 381,269 129,704 -6,385,534 -4,822,904 171,238,248 1,700,273 44,200,845
Sep 2025 627,747 261,734 -3,803,465 -2,126,595 177,289,528 2,177,309 43,131,683

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,203,839
Investing CF
$-3,376,807
Financing CF
$10,742,408
CapEx
$-173,704
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.19
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-40,950,247
Inventory
$594,288
Receivables
$347,897
ST Investments
$0
EBIT TTM
$-17,136,583
Pretax Income TTM
$-17,633,378
Interest Exp TTM
$496,795
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,808,743
EBITDA
$-7,419,085
Free Cash Flow
$-2,679,485
Enterprise Value
$31,666,800
Total Cash
$1,499,603
Total Debt
$5,462,785
Shares Out
35,118,692
Trailing EPS
$-0.37
Book Value
$2.92
ROE
-11.3%
ROA
-6.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,905,805 -18,336,003 -18,010,899 171,238,248 44,200,845 77,635,615 -4,328,034
Dec 2024 3,530,303 -11,692,197 -10,328,910 175,239,579 32,031,363 143,208,216 -1,849,474
Dec 2023 0 -1,830,700 403,780 36,627,733 4,108,272 32,519,461 -818,766
Dec 2022 0 -621,316 1,064,967 120,757,699 21,659,379 99,098,320 -516,309

TTM Snapshot

Revenues TTM
$1,808,742
NetIncome TTM
$-10,729,865
OpCashFlow TTM
—
Assets (Latest)
$166,623,360
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
XAIR Beyond Air, Inc. $3.35M $2.01 —
NVNO enVVeno Medical Corp $4.01M $5.77 —
TUTH Standard Dental Labs Inc. $4.10M $0.13 —
ICU SeaStar Medical Holding Corp $4.15M $0.78 —
BDMD Baird Medical Investment Holdings Ltd $2.94M $0.09 —

News headlines (Yahoo Finance, 1h cache)

OSR Health Exercises $15 Million VXM01 Equity Option, Elects Settlement Through Staged Convertible Notes
2026-11-06 15:11 · Yahoo
OSR Health Board Authorizes Management to Engage with Potential Acquirer of OSRK for Reverse Takeover
2026-11-02 16:05 · Yahoo
Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.
2026-08-27 21:00 · Yahoo
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
2026-08-21 15:45 · Yahoo
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
2026-08-19 19:45 · Yahoo
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
2026-08-19 10:30 · Yahoo
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
2026-08-11 12:52 · Yahoo
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
2026-08-07 19:00 · Yahoo
OSR Health, A Message From the CEO
2026-07-13 16:37 · Yahoo
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
2026-07-02 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.